Wuhan Institute

Wuhan Institute of Biological Products (WIBP) is a prominent Chinese biopharmaceutical company and a key subsidiary of China National Biotec Group (CNBG), which is part of the state-owned Sinopharm. Founded in 1950, the institute has evolved into one of China's largest centers for the research, development, and manufacturing of vaccines and blood-derived products. WIBP gained significant international prominence for developing one of the world's first inactivated COVID-19 vaccines, which received emergency use authorization from the World Health Organization. Its extensive portfolio also includes vaccines for enterovirus 71, Japanese encephalitis, and rabies, supporting both national immunization programs and global health initiatives. The company operates large-scale, GMP-certified manufacturing facilities and continues to advance its pipeline in recombinant technologies and therapeutic biologicals.